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Abstract
Background: Previous studies have shown that the cell polarity protein partitioning defective 3 (Par3) plays an
essential role in the formation of tight junctions and definition of apical-basal polarity. Aberrant function of this
protein has been reported to be involved in epithelial–mesenchymal transition (EMT) and cancer invasion. The aim
of this study was to examine the functional mechanism of Par3 in ovarian cancer.
Methods: First, we investigated the association between Par3 expression level and survival of 50 ovarian cancer patients.
Next, we conducted an in vitro analysis of ovarian cancer cell lines, focusing on the cell line JHOC5, to investigate Par3
function. To investigate the function of Par3 in invasion, the IL-6/STAT3 pathway was analyzed upon Par3 knockdown
with siRNA. The effect of siRNA treatment was assessed by qPCR, ELISA, and western blotting. Invasiveness and cell
proliferation following treatment with siRNA against Par3 were investigated using Matrigel chamber, wound healing, and
cell proliferation assays.
Results: Expression array data for ovarian cancer patient samples revealed low Par3 expression was significantly
associated with good prognosis. Univariate analysis of clinicopathological factors revealed significant association between
high Par3 levels and peritoneal dissemination at the time of diagnosis. Knockdown of Par3 in JHOC5 cells suppressed cell
invasiveness, migration, and cell proliferation with deregulation of IL-6/STAT3 activity.
Conclusion: Taken together, these results suggest that Par3 expression is likely involved in ovarian cancer progression,
especially in peritoneal metastasis. The underlying mechanism may be that Par3 modulates IL-6 /STAT3 signaling. Here,
we propose that the expression of Par3 in ovarian cancer may control disease outcome.
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Background
Ovarian cancer is the fifth most frequent cause of cancer-
related deaths among women worldwide [1]. The estimated
annual incidence of ovarian cancer is approximately
225,000 women, resulting in 140,200 deaths per year [2].
The prognosis for advanced disease has not improved sig-
nificantly in more than two decades [3], suggesting that a
better understanding of progression and metastasis mecha-
nisms of ovarian cancer is critical for determining new ways
to prevent, diagnose, and treat this disease.
Loss of polarity and epithelial cell organization is a
hallmark of carcinoma invasion and metastasis [4–6].
Loss of polarity is considered the initial step of the
epithelial mesenchymal transition (EMT), which is
characterized by the loss of cell-cell adhesion and
apical-basal cell polarity, along with increased cell
motility [4, 7–11].
Three major complexes involved in regulating epithe-
lial cell apical-basal polarity have been described: the
Crumbs complex and Par complex, which are found
apically, and the Scribble complex, located at the
basolateral membrane [4, 12, 13]. Among these three
polarity complexes, the Par complex is the best-studied
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[5, 14–16]. The Par complex consists of three proteins:
Par3, Par6, and aPKC (atypical protein kinase C). Par3
is essential for the delivery of aPKC to the apical sur-
face through binding of Par3 to the adaptor protein
Par6, which forms a constitutive complex with aPKC
[17, 18]. This complex is involved not only in the for-
mation of apical-basal polarity, but also in cell prolifer-
ation, migration, and asymmetric cell division [19–21].
Recent studies have identified the Par complex as an
important regulator in tumorigenesis and metastasis
[22–29]. However, the involvement of Par3 in this process
may be highly context-dependent. Genome-wide screening
for microdeletions revealed that the region containing the
Par3 gene (PARD3) is deleted in lung, head and neck, and
esophageal squamous cell carcinoma cell lines [29, 30]. In
breast, esophageal, and lung cancers, Par3 seems to act as a
tumor suppressor [22, 23, 25], whilst in clear-cell renal car-
cinoma, Par3 overexpression is associated with poor prog-
nosis [27, 28]. In skin cancer, Par3 may act as a tumor
suppressor or tumor promoter depending on the tumor
type [24]. The detailed mechanism of how Par3 is involved
in tumorigenesis and invasion may depend on tumor type
and is still to be elucidated. The Rac1/JNK proliferation
pathway and the IL-6/STAT3 pathway may be key for un-
derstanding the functions of Par3 in promoting cancer
growth [22, 25, 31, 32].
In ovarian cancer, overexpression of aPKC is known to be
associated with poor prognosis [33, 34] but there has been
little research on the function of Par3 in pathogenesis. The
goal of this study was to analyze the functions of Par3 and
to investigate the Par3-related pathways that might be rele-
vant to the clinical outcome and to understanding the
pathogenesis of epithelial ovarian cancer.
Methods
Antibodies and reagents
The following antibodies were used at the dilution indi-
cated. For western blotting: anti-Par3 Millipore #07-330
(1:500) was purchased from Merck Millipore (Darmstadt,
Germany); anti-alpha Tubulin sc-8035 (1:500), anti-
Vimentin (V9) sc-6260 (1:500), and anti-CD71(TFR)
(3B82A1):sc-32272 (1:500) were purchased from Santa
Cruz Biotechnology (Texas, USA); anti-total Stat3 124H6
CS#9139 (1:1000) and anti-phospho Stat3 (Tyr705) (D3A7)
CS#9145 (1:1000) were purchased from Cell Signaling
Technologies (Massachusetts, USA); and anti-E-Cadherin
BD 610181 (1:500) was purchased from BD (California,
USA). For immunofluorescent analysis: anti-Par3 ab64646
(1:100) was purchased from Abcam (Massachusetts, USA)
and anti-phospho Stat3 (Tyr705) (D3A7) CS#9145 (1:100)
was purchased from Cell Signaling Technologies. The
STAT3 Inhibitor S3I-201 (SC-204304) was purchased from
Santa Cruz Biotechnology.
Cell culture
Ovarian cancer cell lines were maintained in the following
media supplemented with 10% fetal bovine serum (FBS,
Life Technologies, California, USA) and antibiotics (Anti-
biotic-Antimycotic Mixed Stock Solution, Nacalai Tesque,
Kyoto Japan). JHOC5 was maintained in Dulbecco's modi-
fied Eagle medium: Nutrient Mixture F-12 (DMEM/F-12,
Life Technologies, California, USA). HaCaT and SKOV3
were maintained in Dulbecco’s modified Eagle medium
(DMEM, Wako, Osaka Japan). OVISE, OVTOKO, and
TOV21 were maintained in RPMI (Wako, Osaka Japan).
RMG1 was maintained in F-12 (Life Technologies). All
cells were grown in a humidified tissue culture incubator
at 37 °C in 5% CO2.
Transfections
Small Interfering RNAs were transfected using Stealth
RNAi against PAR3 (HSS125534, HSS183488, HSS183489),
STAT3 (HSS186130, HSS186131, HSS110279), or non-
targeting siRNA (Stealth RNAi siRNA Negative Control,
Med GC, Life Technologies) as a control. When cells were
60–70% confluent, transfections were performed using Li-
pofectamine RNAiMAX (Life Technologies), Opti-MEM
Reduced Serum Medium (Life Technologies), and a final
concentration of 20 nmol/L siRNAs, according to the man-
ufacturer’s instructions. After 5 h of incubation, the trans-
fection medium was changed to normal culture medium
without antibiotics. The cells were incubated for 48 h and
then subjected to experimentation. Transfection experi-
ments were repeated at least 3 times.
Wild type myc-tagged Par3 was transfected using Effec-
tene Transfection Reagent (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. The plasmid
was kindly provided by Dr. Vjeko Tomaić (International
Centre for Genetic Engineering and Biotechnology, Italy).
Immunoblotting
Cells were lysed by incubation in Lysis buffer (Cell Signal-
ing Technologies #9803) containing protease inhibitor
cocktail (Nacalai Tesque, Kyoto Japan) and phosphatase in-
hibitor cocktail (Roche, Basel, Switzerland) on ice for
5 min. Lysates were then sonicated briefly and centrifuged
at 14,000 rpm at 4 °C for 10 min. The supernatants were
analyzed as follows: for SDS-PAGE, 20 μg of protein was
loaded in each well. For immunoblotting, 0.45 μm PVDF
membranes (Merck Millipore) were used. The membranes
were blocked in 5% milk/TBS-T (TBS containing 0.1%
Tween-20) for 1 h at 20–25 °C followed by incubation with
the appropriate primary antibody diluted in 5% milk/TBS-
T or 5% BSA/TBS-T for the appropriate time according to
the manufacturer’s instructions. After several washes with
TBS-T, membranes were incubated with the appropriate
HRP-conjugated secondary antibody in 5% milk/TBS-T at
20–25 °C for 1 h. Blots were developed using Immobilon
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Western Chemiluminescent HRP substrate (Merck
Millipore) according to the manufacturer's instructions.
Subcellular fractionation assays
To obtain cytoplasmic, nuclear, and membrane fractions
from the cells, a subcellular fractionation assay was per-
formed using the Calbiochem ProteoExtract Fractionation
Kit (Merck Millipore) according to the manufacturer's in-
structions. To inhibit phosphatase activity during lysate
preparation, phosphatase inhibitor cocktail (Roche, Basel,
Switzerland) was used.
Reverse transcription and qPCR
Total RNA was extracted from the cell lines using a Cul-
tured Cell Total RNA Purification Mini Kit (FAVORGEN,
Ping Tung, Taiwan) followed by reverse transcription using
ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka,
Japan) according to manufacturer’s instructions. cDNA was
amplified for 40 cycles in a LightCycler 480 instrument
(Roche, Basel, Switzerland) using LightCycler 480 SYBR
Green I Master reagent (Roche). The primer sets used for
qPCR are: for Par3, 5′-CGCTTGGAACATGGAGATGG-3
and 5′-ATCTCTGGGCTCTGGGTACC-3, for GAPDH,
5′-GAAAGGTGAAGGTCGGAGTC-3 and 5′-GAAGAT
GGTGATGGGATTTC-3. mRNA levels of each gene were
normalized to GAPDH mRNA as an internal standard.
Expression levels were calculated by the comparative
Ct method using GAPDH as the endogenous reference
gene.
Invasion assay
JHOC5 cells were treated with siRNA against Par3,
STAT3, or negative control siRNAs, and then incubated
for 48 h. Cells were trypsinized and dissociated from
dishes, then used for invasion assays. Matrigel invasion
assays were performed using 24-well BioCoat Matrigel
invasion chambers (Corning international, NY USA) ac-
cording to the manufacturer’s instructions. Briefly, lower
chambers were filled with 750 μL of DMEM/F12 with
10% FBS and chemical reagents. Cells in 500 μL of FBS-
free medium were applied to the upper chamber and in-
cubated for 24 h. After incubation, the cells remaining
in the upper chamber were removed with cotton swabs
and the cells that had invaded through the Matrigel were
stained with a Diff Quik staining kit (Sysmex, Hyogo,
Japan). Matrigel membranes were cut from the upper
chamber and placed on microscope slides, then observed
with an optical microscope.
Cell migration assay
Cells were seeded onto 6-well culture plates and grown
as a monolayer until 100% confluent. A scratch was
made on a uniform layer of cells using a sterile micro-
pipette tip followed by one PBS wash to remove debris.
Photographs of the same area of the wound were taken
after 8 h (for siPar3) or 14 h (for siSTAT3), to measure
the width of the wound using a fluorescence microscope
(BZ-9000; Keyence, Osaka, Japan).
Immunofluorescence and confocal microscopy
For immunofluorescence, cells were grown on glass cover-
slips until 80% confluence and fixed in 4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 20 min at
room temperature. After washing with PBS, the cells were
permeabilized in PBS/0.1% Triton X-100 at room
temperature for 5 min or 100% methanol at -20 °C for
10 min depending on which primary antibody was being
used. Then, the samples were washed extensively in PBS
and incubated with the appropriate primary antibody
diluted in antibody dilution buffer (PBS/1% BSA/0.3% Tri-
ton X-100) for 1 h at room temperature or at 4 °C over-
night. After several PBS washes, samples were incubated
with the appropriate Alexa Fluor 488- or 548-conjugated
secondary antibodies for 1 h at room temperature. After
several PBS washes, the coverslips were mounted on glass
slides. Cells were visualized using a Zeiss Axiovert 100 M
microscope (Zeiss, Milan, Italy) attached to a LSM 510 con-
focal unit.
Cell proliferation assay
To analyze the effect of Par3 or STAT3 knockdown on
cell proliferation, cell proliferation assays were per-
formed. Five thousand cells were seeded into each well
of 96-well plates after 48 h of siRNA transfection. Cell
Counting Kit-8 using the tetrazolium salt WST-8 [2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt (Dojindo,
Tokyo, Japan) was used to quantify the number of cells
by monitoring the changes in the absorbance at 450 nm,
which were normalized relative to the absorbance of
cells transfected with non-targeting siRNA.
Enzyme-linked immunosorbent assay (ELISA)
To analyze the effect of Par3 knockdown on IL-6 levels,
an ELISA for IL-6 was performed. Five thousand cells
were seeded into each well of 96-well plates followed by
incubation for 24 h. Cells were then transfected with
siRNA against Par3, and 48 h later, the supernatant was
collected for ELISA analysis. Human IL-6 DuoSet ELISA
Kit (R&D systems, Minnesota, USA) was used for IL6
detection according to the manufacturer’s instruction.
Expression array and statistical analysis
Ovarian cancer samples and genomic cDNA were ob-
tained, and expression array analysis was performed as
previously described [35]. We use probe set 210094_s_at
(GeneChip Human Genome U133 Plus 2.0 Array,
Affymetrix, CA, USA) to measure patient PARD3 mRNA
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levels. For normalization, we used probe intensity data
taken from normal ovarian tissue sample for the probe set
210094_s_at (GeneChip Human Genome U133 Plus 2.0
Array, Affymetrix, Tokyo, Japan) indicating the expression
level of PARD3 mRNA. Then we widened the parameter
of normal values by 10% and regarded this value as “inter-
mediate.” Measured values of PARD3 mRNA above this
range were regarded as “high expression,” and below the
range were regarded as “low expression.” All patients
provided written informed consent for the research use of
their samples, and the collection and use of tissues for
this study were approved by the Human Genome, Gene
Analysis Research Ethics Committee at the University of
Tokyo.
Briefly, samples from 50 patients (22 clear-cell carcin-
omas, 16 serous adenocarcinomas, and 12 endometrioid
carcinomas) who underwent primary tumor resection at
the University of Tokyo Hospital were used (Table 1). All
patients received primary surgery, including hysterectomy,
bilateral salpingo-oophorectomy, and omentectomy, to-
gether with systematic lymphadenectomy (when mass
reduction was completely or optimally achieved). The
patients with stage IC–IV received six to eight cycles
of adjuvant chemotherapy (paclitaxel and carboplatin).
Fresh-frozen tumor samples were embedded in OCT
(optimum cutting temperature) compound, and 4-mm
thick tissue sections were stained with hematoxylin
and eosin. Tissue sections with a high proportion of car-
cinoma cells (>50%) were reviewed by a pathologist and
selected for DNA and total RNA extraction. Genomic
DNA was isolated from tumor sections using a QIAamp
DNA Mini Kit (Qiagen), according to the manufacturer’s
protocol. A Fisher’s exact test was used to evaluate the as-
sociation between Par3 expression and stage, tumor grade,
dissemination, and sites of metastasis. All tests were two-
sided and p-values of 0.05 or less were considered statisti-
cally significant. Statistical analyses were performed using
the JMP12 statistical program (SAS Institute, Cary, NC).
Kaplan-Meier plots for progression-free survival (PFS)
and overall survival (OS) were plotted and analysis was
done using the log-rank test.
Results
Low Par3 expression is associated with good prognosis in
ovarian cancer patients
First, we analyzed the expression microarray data to inves-
tigate the relevance of Par3 expression in ovarian cancer
prognosis. Samples from 50 ovarian cancer patients (22
clear-cell carcinomas, 16 serous adenocarcinomas, and 12
endometrioid carcinomas) were analyzed. The characteris-
tics and histologic data of study participants are shown in
Table 1. In univariate analysis with a hazard ratio and
95% confidence interval, high Par3 expression was signifi-
cantly associated with advanced stage and peritoneal
dissemination at diagnosis, but it was not associated with
lymph node metastasis or distant metastasis (Table 2).
Moreover, low Par3 expression was strongly associated
with good OS and PFS (Fig. 1). These results suggest that
cellular Par3 expression may promote peritoneal metasta-
sis in the majority of ovarian cancer patients.
Par3 is stably expressed in the cytoplasm of JHOC5 cells
Par3 protein is a tight junction protein that localizes to the
membranes of epithelial cells [36, 37]. However, mislocali-
zation of Par3 protein is thought to disrupt normal cell
functions including the formation of cell polarity, cell pro-
liferation, and migration [19, 22–26]. First, we analyzed the
protein level of Par3 in seven ovarian cancer cell lines, in-
cluding JHOC5 (clear-cell adenocarcinoma) (Fig. 2a). The
level of Par3 expression varied among the ovarian cancer
cell lines examined, and it was the strongest in JHOC5 cells.
Therefore, we chose JHOC5 cells for further analysis of
Par3 function in ovarian cancer. Subcellular fractionation
assays showed that Par3 protein was present in the nucleus,
as well as the cytoplasm and membranes (Fig. 2b). Expres-
sion was particularly strong in the cytoplasm and nucleus
of JHOC5 cells. Immunofluorescence staining revealed that
Table 1 Patient characteristics (n = 50)
No. Patients (n = 50)
Age, median (range), yr 57 (32–80)
Follow-up period (m) 59.1 (2–120)
FIGO
Stage I 25 (50%)
Stage II 4 (8%)
Stage III 12 (24%)
Stage IV 9 (18%)
Histology
High-grade serous 16 (30%)
Endometrioid 12 (8%)
Clear cell 22 (44%)
Dissemination and metastasis at diagnosis (overlapped, depending on
the cases)
Dissemination 18 (36%)
Lymph node metastasis 12 (24%)
Distant metastasis 3 (0.6%)
Recurrent site (overlapped, depending on the cases)
Dissemination 17 (34%)
Lymph node metastasis 10 (20%)
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Par3 localizes in the nucleus, cytoplasm, and focally at the
membrane in JHOC5 cells (Fig. 2c). HaCaT cells, a normal
immortalized keratinocyte line, were used as a control
because these cells make normal cell contacts. As shown
in Fig. 2c, nuclear localization of Par3 was clearly seen in
JHOC5 cells, but was not detectable in HaCaT cells, con-
sistent with a previous study [26]. These results suggested
that Par3 was mislocalized in ovarian cancer cells.
Par3 promotes invasion and cell proliferation ability in
JHOC5 cells
Next, we investigated whether Par3 has a role in migration,
invasion, and cell proliferation in JHOC5 cells. To accom-
plish this, we knocked down Par3 using siRNA. JHOC5
cells were transfected with three different siRNAs against
Table 2 Correlation between high expression of Par3 and
clinical features
Stage P value
Stage I, II vs Stage III, IVa P = 0.0352*
Dissemination and site of metastasis at diagnosis
Dissemination P = 0.0381*
Lymph node metastasis P = 0.1469
Distant metastasis P = 0.2914
*P < .05 considered significant
Fig. 1 Low Par3 expression is associated with good overall survival and prognosis. We analyzed the duration of response; overall survival (OS), and
progression-free survival (PFS) using resected samples from 50 ovarian cancer patients (22 clear-cell carcinomas, 16 serous adenocarcinomas, and 12
endometrioid carcinomas). All patients received primary surgery, including hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, together
with systematic lymphadenectomy (when mass reduction was completely or optimally achieved). The patients with stage IC–IV received six to eight cycles
of adjuvant chemotherapy (paclitaxel and carboplatin). There were three patients with stage Ia who did not receive any chemotherapy. In this study, the
patients with neoadjuvant chemotherapy were excluded. Tissue sections with a high proportion of carcinoma cells (>50%) were reviewed by a pathologist
and selected for DNA and total RNA extraction. Kaplan-Meier plots for overall survival (a) and progression free survival (b) were plotted and analysis was
performed using the log-rank test. Low Par3 expression was significantly associated with good prognosis (OS: P= 0.002; PFS: P= 0.0033)
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Par3. qPCR analysis showed that siRNA B seemed to be
the most effective in knocking down Par3 (Fig. 3A-1),
therefore, we decided to use it for further studies. siPar3 B
also sufficiently knocked down the Par3 protein level,
as determined by western blot (Fig. 3A-2).
Invasion assays were performed using a Matrigel Invasion
assay kit. In this study, cells invaded through an extracellu-
lar matrix barrier using 10% FBS as a chemoattractant, and
cell invasion was assessed after 24 h. JHOC5 cells showed
decreased invasive ability following siRNA knockdown of
Par3 (Fig. 3B-1,2). In a wound healing assay, siPar3-treated
JHOC5 cells showed delayed cell migration (Fig. 3c). Fur-
thermore, in the cell proliferation assay, Par3 knockdown
suppressed JHOC5 cell proliferation (Fig. 3d). The effect of
Par3 knockdown was confirmed by western blotting at 24,
48,72 h (Additional file 1: Figure S1).
Par3 affects IL-6 and STAT3 activation in JHOC5 cells
Having shown that Par3 is involved in promoting cell pro-
liferation, migration, and invasion, we were interested in
Fig. 2 Expression pattern of Par3 in JHOC5 ovarian cancer cells. a Par3 protein level in seven ovarian cancer cell lines (JHOC5, JHOC8, OVISE, OVTOKO,
TOV21, RMG1, and SKOV3). Semiconfluent cells were harvested for western blotting. Cell lysates were resolved by SDS-PAGE and immunoblotted with an
antibody against Par3 or E-Cadherin. Blots are representative of at least three experiments. b Subcellular fractionation assay. JHOC5 cells were fractioned
into cytosol (F1), membrane (F2), nucleus (F3), and cytoskeleton (F4) pools and Par3 was detected by western blotting. Loading controls used were α-
Tubulin, TFR, p84, and vimentin for the cytosol, membrane, nucleus, and cytoskeleton fractions, respectively. c Immunofluorescence analysis of Par3
expression in JHOC5 cells and control HaCaT cells. Cells were grown on coverslips and then fixed and stained with the anti-Par3 antibody and DAPI.
Scale bar indicates 10 μm
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further investigating its molecular mechanism. To do this,
we focused on the IL-6/STAT3 pathway. Western blot
analysis revealed that STAT3 activation (phosphorylated
STAT3 (Tyr705)) decreased upon the loss of Par3 in
JHOC5 cells (Fig. 4a). ELISA analysis demonstrated that
siPar3 also significantly decreased IL-6 secretion by
JHOC5 cells (Fig. 4b). Based on these results, we reasoned
that the IL-6/STAT3 pathway might be important for
regulating Par3 function in certain types of ovarian cancer
cells. To confirm whether Par3 regulates the STAT3 path-
way, we analyzed the effect of wild type Par3 overexpres-
sion on STAT3 activation. As expected, Par3 upregulated
Fig. 3 Downregulation of Par3 suppressed invasion and proliferation of JHOC5 cells. a Effect of siRNA against Par3. JHOC5 cells were transfected with
Stealth RNAi against PAR3 (A: HSS125534, B: HSS183488, C: HSS183489) or control siRNA for 48 h. Total RNA was reverse transcribed and PARD3 mRNA
levels (Par3) were measured by a quantitative reverse transcription polymerase chain reaction. Expression was normalized to the expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are the mean (±SEM) of three independent experiments (A-1). siPar3-B was chosen for further
analysis. Cells were transfected with siControl or siPar3, then 48 h after transfection, Par3 and α-Tubulin expression was analyzed by western blotting. The
experiments were repeated at least 3 times (A-2). b Invasion assay. JHOC5 cells were transfected with the Par3 siRNA (siPar3) or control siRNA (siControl).
Transfected cells were seeded in a Matrigel-coated Boyden chamber 48 h after transfection, and were allowed to invade for 24 h. Matrigel membranes
were observed with an optical microscope. Scale bar indicates 100 μm (B-1). Numbers of cells invaded through matrigels were counted. Data are the mean
(±SEM) of five different microscopic fields. The data is the representative of three independent experiments (B-2). c) Wound healing assay. JHOC5 cells were
transfected with the Par3 siRNA (siPar3) or control siRNA (siControl), seeded onto 6-well culture plates, and grown as a monolayer for 48–60 h until 100%
confluent. A scratch assay was then performed. Images of the same area of the wound were taken after 8 h to measure the width of the wound using
fluorescence microscope. The data is the representative of three independent experiments. d Cell proliferation assay. To analyze the effect of Par3
knockdown on cell proliferation, 5000 cells were seeded onto 96-well plates 48 h after siRNA transfection. Cell Counting Kit-8 (Sigma Aldrich) was used to
examine proliferation at 24, 48 and 72 h. Data are the mean (±SEM) of three wells. The data shown is representative of three independent experiments
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the level of phospho-STAT3 in JHOC5 cells (Fig. 4c).
Furthermore, analysis of siSTAT3-treated JHOC5 cells
in cell invasion assays, wound healing assays, and cell
proliferation assays confirmed the STAT3-dependence
of JHOC cells in these assays (Fig. 5a-c). In addition,
treatment with a STAT3 inhibitor (S3I-201: SC-204304)
suppressed cell proliferation (Fig. 5d). Taken together,
these results indicated that JHOC5 cell invasion, prolife-
ration, and migration were dependent on the STAT3
pathway.
We also determined whether STAT3 could regulate
Par3 expression; western blot analysis showed that Par3
expression was downregulated in the presence of STAT3
inhibitor (S3I-201) in JHOC5 cells (Fig. 5e).
Fig. 4 Par3 regulates IL-6/STAT3 pathway. a Effect of siPar3 on STAT3 expression. JHOC cells were transfected with siPAR3 or control siRNA (siControl). Total
cell extracts were then obtained after 48 h, and phospho-STAT3, total STAT3, and α-Tubulin proteins were detected by western blotting. The right-hand
histogram shows the relative intensities of the blots of pSTAT3 normalized to α-Tubulin. Data are the mean (±SEM) of three independent experiments. b
Effect of siPar3 on IL-6 secretion. JHOC5 cells were transfected with siPar3 or control siRNA for 48 h, then conditioned media were collected for ELISA analysis
of IL-6. Data are the mean (±SEM) of three independent experiments. c Effect of Par3 overexpression on STAT3 expression. JHOC5 cells were transfected with
pcDNA 3.1 (empty vector) or myc-Par3 for 24 h and Par3, phospho-STAT, total STAT, and α-Tubulin levels were analyzed by western blotting
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Fig. 5 STAT3 regulates Par3 expression. a Invasion assay. JHOC5 cells were transfected with the STAT3 siRNA (siSTAT3) or control siRNA (siControl). The
transfected cells were placed in a Matrigel-coated Boyden chamber 48 h after transfection, and allowed to invade for 24 h. Matrigel membranes were
observed with an optical microscope. Scale bar indicates 200 μm. b Wound healing assay. JHOC5 cells were transfected with STAT3 siRNA (siSTAT3) or
control siRNA (siControl), seeded onto 6-well culture plates, and grown as a monolayer for 48–60 h until 100% confluent. A scratch assay was then
performed. Images of the same area of the wound were taken after 14 h to measure the width of the wound using fluorescence microscope. Data is
representative of three independent experiments. c Cell proliferation assay. To analyze the effect of STAT3 knockdown on cell proliferation, 5000 cells were
seeded onto 96-well plates 48 h after siRNA transfection. A Cell Counting Kit-8 (Sigma Aldrich) was used to examine proliferation. Data are the mean
(±SEM) of four wells. The data shown is representative of three independent experiments. d Effect of STAT3 inhibition on JHOC5 cell proliferation. 5000 cells
were seeded onto 96-well plates and incubated for 24 h. Then, they were grown with or without a STAT3 inhibitor (S3I-201) at the doses indicated. Cell
proliferation was determined after 24, 48, and 72 h, using a Cell Counting Kit-8 (Sigma Aldrich). Data are the mean (±SEM) of four wells. Showing data
is representative of two independent experiments. e Effect of STAT3 inhibition on Par3 expression. JHOC5 cells were treated with or without
S3I-201 (100 μM) for 48 h. Cells were lysed and then phospho-STAT3, total STAT3, Par3, and α-Tubulin protein levels were detected by western
blotting. f Immunofluorescent analysis of pSTAT3 expression. JHOC5 cells were grown on coverslips and then fixed and stained with
anti-phospho-STAT3 and DAPI. Scale bar indicates 10 μm
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Furthermore, immunofluorescence analysis showed that
active STAT3 (pSTAT3) localizes to the nucleus in JHOC
cells (Fig. 5f). As we demonstrated in Fig. 2c, Par3 localizes
to both the nucleus and cytoplasm in JHOC5 cells. Taken
together, these results implied that Par3 interacts either dir-
ectly or indirectly with active STAT3 and IL-6, suggesting
that Par3 may regulate cellular invasion and proliferation in
JHOC5 cells via the IL-6/STAT3 pathway.
Discussion
In the present study, we observed that high Par3 expres-
sion was significantly associated with advanced stage
and peritoneal dissemination at diagnosis. Furthermore,
low Par3 expression was associated with good prognosis.
We also showed that Par3 promotes invasive properties
in JHOC5 cells through the IL-6/STAT3 pathway.
Previous studies have reported diverse functions of Par3,
including regulation of cell proliferation, cell polarity, cell
migration, and cell invasion in a variety of different cancer
cell types. Recently, polarity gene disruption has been ob-
served in a subset of human cancers using genome-wide
screening strategies like high-resolution copy number array
analysis [30]. The results indicate that dysregulation of cell
polarity affects cancer progression. To date, disruption of
polarity complexes including Scribble, Par3, and Crumbs
complexes has been considered essential for cancer devel-
opment [7, 12, 38–40]. Among these complexes, the Par3
complex is thought to be a master regulator controlling
ubiquitous functions [41, 42]. Considering the role of Par3
in carcinogenesis, it has recently been shown that depletion
of Par3 along with the expression of oncogenic Notch and
Ras in murine mammary gland cells is associated with a
tumor-promoting effect and metastasis [22]. Moreover,
Par3 inactivation was discovered in 8% of squamous cell
lung cancers and Par3 immunohistochemical analysis in
lung cancers also demonstrated its contribution to cancer
development [25]. In contrast, a study of skin tumorigenesis
demonstrated that Par3 deficiency in mice resulted in a pre-
disposition toward keratoacanthomas, a common low-
grade skin tumor from various cellular origins [24]. Other
studies reported that Par3 overexpression was associated
with cancer initiation [27]. All these results indicate that
Par3 can play various roles in regulating tumor formation.
Previous studies implied that Par3 disruption in squa-
mous cell carcinomas and glioblastomas was caused by
mutations of the PARD3 gene [30]. However, according to
TCGA data [43], only one such mutation was detected in
316 cases of ovarian serous adenocarcinoma. These con-
flicting observations in various cancers including ovarian
cancer make it difficult to investigate Par3 function.
In this study, microarray analysis of 50 ovarian cancer
cases indicated that low Par3 expression was associated
with good prognosis (Fig. 1). We also observed that Par3
might be mislocalized to the cytoplasm and the nucleus
(Fig. 2b and c). Furthermore, Par3 expression promotes
cell invasion, migration, and cell proliferation in JHOC5
cells (Fig. 3b-d). We investigated the underlying mech-
anism of these Par3 functions by focusing on the IL-6/
STAT3 pathway. Par3 knockdown suppressed STAT3 ac-
tivation and IL-6 levels (Fig. 4a, b). Therefore, Par3 may
exert its oncogenic potential through the STAT3 path-
way in a subset of ovarian cancer cells that are similar to
JHOC5 cells. Although at present, we have not been able
to investigate the mechanism by which Par3 regulates
the IL-6/STAT3 pathway, previous studies have shown
that the Par3 complex has a strong relationship with the
STAT3-IL-6 axis in mammalian cells [32]. Here, we pro-
vide the first indication that Par3 is associated with ovar-
ian cancer progression through the IL-6/STAT3 pathway.
Clearly, this ovarian cancer model is limited, since
we have not been able to compare the function and
localization of Par3 to normal ovarian cells. The origin
of ovarian cancer is controversial [43] which makes it
difficult to define “normal” ovarian cell lines compared
with malignant cell lines, although ovarian surface epi-
thelial (OSE) cells have been used as a model to study
ovarian carcinogenesis. As an alternative, we used
HaCaT cells, immortalized human keratinocytes, to see
where Par3 is normally localized. Intriguingly, as seen
in Fig. 2c, we found that Par3 is expressed in the nu-
cleus as well as the cytoplasm in JHOC5 cells. As far
as we know, this is the first observation of nuclear
Par3 expression in ovarian cancer cells.
Though the exact mechanism through which Par3
affects tumor formation remains to be investigated,
our observations may explain how Par3 may be in-
volved in tumor malignancy, which could be largely
dependent on the reconstitution of STAT3 signaling
in ovarian cancer. Recently, it was reported that aber-
rant activation of the STAT3 pathway is found in
more than 70% of ovarian cancers and was associated
with decreased OS [44]. Moreover, therapeutic strat-
egies targeting STAT3 signaling are being developed
[45]. In terms of developing prognostic biomarkers,
our study suggests that Par3 could be a candidate for
ovarian cancer management, especially in monitoring
STAT3 signaling in metastatic ovarian cancer.
Conclusions
This study highlights the association between low
Par3 expression and good prognosis. It also showed
Par3 expression is likely involved in ovarian cancer
progression, especially in peritoneal metastasis. The
underlying mechanism may be that Par3 modulates
IL-6 /STAT3 signaling. Par3 could be a candidate for
prognostic biomarkers in ovarian cancer in monitor-
ing STAT3 signaling.
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Additional file
Additional file 1: Figure S1. Par3 is sufficiently knocked down at 24,
48, and 72 h. JHOC cells were transfected with siPar3 or control siRNA
(siControl). Total cell extracts were then taken after 24, 48, and 72 h. Par3
and α-Tubulin protein were detected by western blotting. (PPTX 139 kb)
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